References
[1] Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424
[2] Lichtenstein P, Holm NV, Verkasalo PK et al. Environmental and
heritable factors in the causation of cancer – analyses of cohorts of
twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:
78–85
[3] Jasperson KW, Tuohy TM, Neklason DW et al. Hereditary and familial
colon cancer. Gastroenterology 2010; 138: 2044–2058
[4] Hampel H, Frankel WL, Martin E et al. Feasibility of screening for
Lynch syndrome among patients with colorectal cancer. J Clin Oncol
2008; 26: 5783–5788
[5] van Leerdam ME, Roos VH, van Hooft JE et al. Endoscopic manage-
ment of polyposis syndromes: European Society of Gastrointestinal
Endoscopy (ESGE) Guideline. Endoscopy 2019; 51: 877–895
[6] Armelao F, de Pretis G. Familial colorectal cancer: a review. World J
Gastroenterol 2014; 20: 9292–9298
van Leerdam Monique E. et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer… Endoscopy
Guideline
[7] Atkins D, Best D, Briss PA et al. Grading quality of evidence and
strength of recommendations. BMJ 2004; 328: 1490
[8] Dumonceau JM, Hassan C, Riphaus A et al. European Society of Gas-
trointestinal Endoscopy (ESGE) guideline development policy.
Endoscopy 2012; 44: 626–629
[9] Linstone HA, Turoff M. The Delphi method: Techniques and applica-
tions. Addison-Wesley Educational Publishers Inc; 1975
[10] Jones J, Hunter D. Consensus methods for medical and health servi-
ces research. BMJ 1995; 311: 376–380
[11] Likert R. A technique for the measurement of attitudes. Arch Psychol
1932; 22: 5–55
[12] Moreira L, Balaguer F, Lindor N et al. Identification of Lynch syn-
drome among patients with colorectal cancer. JAMA 2012; 308:
1555–1565
[13] Win AK, Jenkins MA, Dowty JG et al. Prevalence and penetrance of
major genes and polygenes for colorectal cancer. Cancer Epidemiol
Biomarkers Prev 2017; 26: 404–412
[14] Ramsoekh D, Wagner A, van Leerdam ME et al. Cancer risk in MLH1,
MSH2 and MSH6 mutation carriers; different risk profiles may influ-
ence clinical management. Hered Cancer Clin Pract 2009; 7: 17
[15] Moller P, Seppala T, Bernstein I et al. Cancer incidence and survival in
Lynch syndrome patients receiving colonoscopic and gynaecological
surveillance: first report from the prospective Lynch syndrome da-
tabase. Gut 2017; 66: 464–472
[16] Moller P, Seppala TT, Bernstein I et al. Cancer risk and survival in
path_MMR carriers by gene and gender up to 75 years of age: a re-
port from the Prospective Lynch Syndrome Database. Gut 2018; 67:
1306–1316
[17] Edelstein DL, Axilbund J, Baxter M et al. Rapid development of colo-
rectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol
Hepatol 2011; 9: 340–343
[18] Jarvinen HJ, Aarnio M, Mustonen H et al. Controlled 15-year trial on
screening for colorectal cancer in families with hereditary nonpoly-
posis colorectal cancer. Gastroenterology 2000; 118: 829–834
[19] de Jong AE, Hendriks YM, Kleibeuker JH et al. Decrease in mortality
in Lynch syndrome families because of surveillance. Gastroenterol-
ogy 2006; 130: 665–671
[20] Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal
cancer rate in families with hereditary nonpolyposis colorectal can-
cer. Gastroenterology 1995; 108: 1405–1411
[21] Barrow P, Khan M, Lalloo F et al. Systematic review of the impact of
registration and screening on colorectal cancer incidence and mor-
tality in familial adenomatous polyposis and Lynch syndrome. Br J
Surg 2013; 100: 1719–1731
[22] Rutter MD, Beintaris I, Valori R et al. World Endoscopy Organization
consensus statements on post-colonoscopy and post-imaging colo-
rectal cancer. Gastroenterology 2018; 155: 909–925.e3
[23] Ahadova A, von Knebel DoeberitzM, Blaker H et al. CTNNB1-mutant
colorectal carcinomas with immediate invasive growth: a model of
interval cancers in Lynch syndrome. Fam Cancer 2016; 15: 579–586
[24] Haanstra JF, Vasen HF, Sanduleanu S et al. Quality colonoscopy and
risk of interval cancer in Lynch syndrome. Int J Colorectal Dis 2013;
28: 1643–1649
[25] Vale Rodrigues R, Claro I, Lage P et al. Colorectal cancer surveillance
in Portuguese families with lynch syndrome: a cohort study. Int J
Colorectal Dis 2018; 33: 695–702
[26] Newton K, Green K, Lalloo F et al. Colonoscopy screening compli-
ance and outcomes in patients with Lynch syndrome. Colorectal Dis
2015; 17: 38–46
[27] de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G et al.
Surveillance for hereditary nonpolyposis colorectal cancer: a long-
term study on 114 families. Dis Colon Rectum 2002; 45: 1588–1594
[28] Vasen HF, Abdirahman M, Brohet R et al. One to 2-year surveillance
intervals reduce risk of colorectal cancer in families with Lynch syn-
drome. Gastroenterology 2010; 138: 2300–2306
[29] van Vugt van Pinxteren MW, van Kouwen MC, van Oijen MG et al. A
prospective study of bowel preparation for colonoscopy with poly-
ethylene glycol-electrolyte solution versus sodium phosphate in
Lynch syndrome: a randomized trial. Fam Cancer 2012; 11: 337–341
[30] Argillander TE, Koornstra JJ, van Kouwen M et al. Features of incident
colorectal cancer in Lynch syndrome. United European Gastroenter-
ol J 2018; 6: 1215–1222
[31] Anyla M, Lefevre JH, Creavin B et al. Metachronous colorectal cancer
risk in Lynch syndrome patients-should the endoscopic surveillance
be more intensive? Int J Colorectal Dis 2018; 33: 703–708
[32] de Jong AE, Nagengast FM, Kleibeuker JH et al. What is the appro-
priate screening protocol in Lynch syndrome? Fam Cancer 2006; 5:
373–378
[33] Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al. Ten years
after mutation testing for Lynch syndrome: cancer incidence and
outcome in mutation-positive and mutation-negative family mem-
bers. J Clin Oncol 2009; 27: 4793–4797
[34] Engel C, Rahner N, Schulmann K et al. Efficacy of annual colono-
scopic surveillance in individuals with hereditary nonpolyposis colo-
rectal cancer. Clin Gastroenterol Hepatol 2010; 8: 174–182
[35] Engel C, Vasen HF, Seppala T et al. No difference in colorectal cancer
incidence or stage at detection by colonoscopy among 3 countries
with different Lynch syndrome surveillance policies. Gastroenterol-
ogy 2018; 155: 1400–1409.e2
[36] Stuckless S, Green JS, Morgenstern M et al. Impact of colonoscopic
screening in male and female Lynch syndrome carriers with an MSH2
mutation. Clin Genet 2012; 82: 439–445
[37] Stoffel EM, Mercado RC, Kohlmann W et al. Prevalence and predic-
tors of appropriate colorectal cancer surveillance in Lynch syn-
drome. American J Gastroenterol 2010; 105: 1851–1860
[38] Sjostrom O, Lindholm L, Tavelin B et al. Decentralized colonoscopic
surveillance with high patient compliance prevents hereditary and
familial colorectal cancer. Fam Cancer 2016; 15: 543–551
[39] Lecomte T, Cellier C, Meatchi T et al. Chromoendoscopic colonos-
copy for detecting preneoplastic lesions in hereditary nonpolyposis
colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005; 3:
897–902
[40] Huneburg R, Lammert F, Rabe C et al. Chromocolonoscopy detects
more adenomas than white light colonoscopy or narrow band ima-
ging colonoscopy in hereditary nonpolyposis colorectal cancer
screening. Endoscopy 2009; 41: 316–322
[41] Rahmi G, Lecomte T, Malka D et al. Impact of chromoscopy on ade-
noma detection in patients with Lynch syndrome: a prospective,
multicenter, blinded, tandem colonoscopy study. American J Gas-
troenterol 2015; 110: 288–298
[42] Bisschops R, Tejpar S, Willekens H et al. Virtual chromoendoscopy
(I-SCAN) detects more polyps in patients with Lynch syndrome: a
randomized controlled crossover trial. Endoscopy 2017; 49: 342–
350
[43] East JE, Suzuki N, Stavrinidis M et al. Narrow band imaging for colo-
noscopic surveillance in hereditary non-polyposis colorectal cancer.
Gut 2008; 57: 65–70
[44] Stoffel EM, Turgeon DK, Stockwell DH et al. Missed adenomas during
colonoscopic surveillance in individuals with Lynch Syndrome (he-
reditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila)
2008; 1: 470–475
[45] Hurlstone DP, Karajeh M, Cross SS et al. The role of high-magnifica-
tion-chromoscopic colonoscopy in hereditary nonpolyposis colo-
rectal cancer screening: a prospective “back-to-back” endoscopic
study. American J Gastroenterol 2005; 100: 2167–2173
van Leerdam Monique E. et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer… Endoscopy
[46] Ramsoekh D, Haringsma J, Poley JW et al. A back-to-back compari-
son of white light video endoscopy with autofluorescence endos-
copy for adenoma detection in high-risk subjects. Gut 2010; 59:
785–793
[47] Schneider JL, Goddard KAB, Muessig KR et al. Patient and provider
perspectives on adherence to and care coordination of lynch syn-
drome surveillance recommendations: findings from qualitative in-
terviews. Hered Cancer Clin Pract 2018; 16: 11
[48] Kaminski MF, Thomas-Gibson S, Bugajski M et al. Performance
measures for lower gastrointestinal endoscopy: a European Society
of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initia-
tive. Endoscopy 2017; 49: 378–397
[49] Kaminski MF, Hassan C, Bisschops R et al. Advanced imaging for de-
tection and differentiation of colorectal neoplasia: European Society
of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2014;
46: 435–449
[50] Ten Broeke SW, van der Klift HM, Tops CMJ et al. Cancer risks for
PMS2-associated Lynch syndrome. J Clin Oncol 2018; 36: 2961–2968
[51] Hendriks YM, Wagner A, Morreau H et al. Cancer risk in hereditary
nonpolyposis colorectal cancer due to MSH6 mutations: impact on
counseling and surveillance. Gastroenterology 2004; 127: 17–25
[52] Plaschke J, Engel C, Kruger S et al. Lower incidence of colorectal
cancer and later age of disease onset in 27 families with pathogenic
MSH6 germline mutations compared with families with MLH1 or
MSH2 mutations: the German Hereditary Nonpolyposis Colorectal
Cancer Consortium. J Clin Oncol 2004; 22: 4486–4494
[53] Sanchez A, Navarro M, Ocaña T et al. Colorectal cancer incidence in
Lynch syndrome patients: first report of a multicenter nation-wide
study. Gastroenterology 2017; 152: S552
[54] Jenkins MA, Dowty JG, Ait OuakrimD et al. Short-term risk of colo-
rectal cancer in individuals with lynch syndrome: a meta-analysis.
J Clin Oncol 2015; 33: 326–331
[55] Lamba M, Ebel R, Hamilton SM et al. 828 – What’s my risk of cancer
doctor? Interval colorectal cancer risk in Lynch syndrome: Results
from the New Zealand National Registry Gastroenterology 2019;
156: S–179
[56] Seppala T, Pylvanainen K, Evans DG et al. Colorectal cancer inci-
dence in path_MLH1 carriers subjected to different follow-up pro-
tocols: a prospective Lynch syndrome database report. Hered Can-
cer Clin Pract 2017; 15: 18
[57] Stupart DA, Goldberg PA, Algar U et al. Surveillance colonoscopy
improves survival in a cohort of subjects with a single mismatch
repair gene mutation. Colorectal Dis 2009; 11: 126–130
[58] Lee G, Lee W, Park Y et al. The surveillance of colorectal adenoma
and carcinoma after colectomy for hereditary nonpolyposis colo-
rectal cancer in a positive DNA mismatch repair gene mutation test.
Dis Colon Rectum 2012; 55: e213
[59] Ten Broeke SW, van Bavel TC, Jansen AML et al. Molecular back-
ground of colorectal tumors from patients with Lynch syndrome
associated with germline variants in PMS2. Gastroenterology 2018;
155: 844–851
[60] Perrod G, Samaha E, Rahmi G et al. Impact of an optimized colono-
scopic screening program for patients with Lynch syndrome: 6-year
results of a specialized French network. Therap Adv Gastroenterol
2018; 11: 1756284818775058
[61] Haanstra JF, Dekker E, Cats A et al. Effect of chromoendoscopy in the
proximal colon on colorectal neoplasia detection in Lynch syndrome:
a multicenter randomized controlled trial. Gastrointest Endosc
2019: doi:10.1016/j.gie.2019.04.227 [Epub ahead of print]
[62] Rivero-Sánchez L, Arnau-Collell C, Herrero J et al. White-light
endoscopy is adequate for Lynch syndrome surveillance in a ran-
domized and non-inferiority study. Gastroenterology 2019:
doi:10.1053/j.gastro.2019.09.003 [Epub ahead of print]
[63] Samaha E, Bellanger J, Dhooge M et al. Sa1900 Comparison of colo-
noscopy with virtual chromoendoscopy using third generation nar-
row band imaging system to chromoendoscopy with indigo carmine
in Lynch syndrome patients (the lynch-chromo study). Gastrointest
Endosc 2018; 87: AB241
[64] Barrow E, Hill J, Gareth Evans D. Cancer risk in Lynch syndrome. Fam
Cancer12: 229–240
[65] Fornasarig M, Magris R, De Re V et al. Molecular and pathological
features of gastric cancer in Lynch Syndrome and familial adenoma-
tous polyposis. Int J Mol Sci 2018: doi:10.3390/ijms19061682
[66] Capelle LG, Van Grieken NC, Lingsma HF et al. Risk and epidemiolo-
gical time trends of gastric cancer in Lynch syndrome carriers in the
Netherlands. Gastroenterology 2010; 138: 487–492
[67] Aarnio M, Salovaara R, Aaltonen LA et al. Features of gastric cancer in
hereditary non-polyposis colorectal cancer syndrome. Int J Cancer
1997; 74: 551–555
[68] Soer EC, Leicher LW, Langers AM et al. Equivalent Helicobacter pylori
infection rates in Lynch syndrome mutation carriers with and with-
out a first-degree relative with gastric cancer. Int J Colorectal Dis
2016; 31: 693–697
[69] Galiatsatos P, Labos C, Jeanjean M et al. Low yield of gastroscopy in
patients with Lynch syndrome. Turk J Gastroenterol 2017; 28: 434–
438
[70] Renkonen-Sinisalo L, Sipponen P, Aarnio M et al. No support for
endoscopic surveillance for gastric cancer in hereditary non-poly-
posis colorectal cancer. Scand J Gastroenterol 2002; 37: 574–547
[71] Fuccio L, Zagari RM, Minardi ME et al. Systematic review: Helicobac-
ter pylori eradication for the prevention of gastric cancer. Aliment
Pharmacol Ther 2007; 25: 133–141
[72] Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and
treating Helicobacter pylori for gastric cancer prevention. Best Pract
Res Clin Gastroenterol 2013; 27: 933–947
[73] Koornstra JJ, Kleibeuker JH, Vasen HF. Small-bowel cancer in Lynch
syndrome: is it time for surveillance? Lancet Oncol 2008; 9: 901–905
[74] Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence
of extracolonic cancers in Lynch syndrome: a report of 121 families
with proven mutations. Clin Genet 2009; 75: 141–149
[75] Bonadona V, Bonaiti B, Olschwang S et al. Cancer risks associated
with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch
syndrome. JAMA 2011; 305: 2304–2310
[76] Vasen HF, Stormorken A, Menko FH et al. MSH2 mutation carriers are
at higher risk of cancer than MLH1 mutation carriers: a study of her-
editary nonpolyposis colorectal cancer families. J Clin Oncol 2001;
19: 4074–4080
[77] Lynch HT, Smyrk TC, Lynch PM et al. Adenocarcinoma of the small
bowel in lynch syndrome II. Cancer 1989; 64: 2178–2183
[78] Parc Y, Boisson C, Thomas G et al. Cancer risk in 348 French MSH2 or
MLH1 gene carriers. J Med Genet 2003; 40: 208–213
[79] Park JG, Kim DW, Hong CW et al. Germ line mutations of mismatch
repair genes in hereditary nonpolyposis colorectal cancer patients
with small bowel cancer: International Society for Gastrointestinal
Hereditary Tumours Collaborative Study. Clinical Cancer Res 2006;
12: 3389–3393
[80] Rodriguez-Bigas MA, Vasen HF, Lynch HT et al. Characteristics of
small bowel carcinoma in hereditary nonpolyposis colorectal carci-
noma. International Collaborative Group on HNPCC. Cancer 1998;
83: 240–244
[81] Schulmann K, Brasch FE, Kunstmann E et al. HNPCC-associated small
bowel cancer: clinical and molecular characteristics. Gastroenterol-
ogy 2005; 128: 590–599
[82] ten Kate GL, Kleibeuker JH, Nagengast FM et al. Is surveillance of the
small bowel indicated for Lynch syndrome families? Gut 2007; 56:
1198–1201
van Leerdam Monique E. et al. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer… Endoscopy
Guideline
[83] Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis
colorectal cancer. Cancer 1993; 71: 677–685
[84] Haanstra JF, Al-Toma A, Dekker E et al. Prevalence of small-bowel
neoplasia in Lynch syndrome assessed by video capsule endoscopy.
Gut 2015; 64: 1578–1583
[85] Saurin JC, Pilleul F, Soussan EB et al. Small-bowel capsule endoscopy
diagnoses early and advanced neoplasms in asymptomatic patients
with Lynch syndrome. Endoscopy 2010; 42: 1057–1062
[86] Haanstra JF, Al-Toma A, Dekker E et al. Incidence of small bowel
neoplasia in Lynch syndrome assessed by video capsule endoscopy.
Endosc Int Open 2017; 5: E622–E626
[87] Hammoudi N, Dhooge M, Coriat R et al. Duodenal tumor risk in
Lynch syndrome. Dig Liver Dis 2019; 51: 299–303
[88] Rex DK, Boland CR, Dominitz JA et al. Colorectal cancer screening:
recommendations for physicians and patients from the U.S. Multi-
Society Task Force on Colorectal Cancer. Gastroenterology 2017;
153: 307–323
[89] Leddin D, Lieberman DA, Tse F et al. Clinical practice guideline on
screening for colorectal cancer in individuals with a family history of
nonhereditary colorectal cancer or adenoma: The Canadian Asso-
ciation of Gastroenterology Banff Consensus. Gastroenterology
2018; 155: 1325–1347.e3
[90] Provenzale D, Jasperson K, Ahnen DJ et al. Colorectal cancer screen-
ing, version 1.2015. J Natl Compr Canc Netw 2015; 13: 959–968;
quiz 68
[91] Wong MCS, Chan CH, Lin J et al. Lower relative contribution of posi-
tive family history to colorectal cancer risk with increasing age: a
systematic review and meta-analysis of 9.28 million individuals.
American J Gastroenterol 2018; 113: 1819–1827
[92] Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of
colorectal cancer for individuals with a family history: a meta-analy-
sis. Eur J Cancer 2006; 42: 216–227
[93] Baglietto L, Jenkins MA, Severi G et al. Measures of familial aggrega-
tion depend on definition of family history: meta-analysis for colo-
rectal cancer. J Clin Epidemiol 2006; 59: 114–124
[94] Johns LE, Houlston RS. A systematic review and meta-analysis of fa-
milial colorectal cancer risk. American J Gastroenterol 2001; 96:
2992–3003
[95] Roos VH, Mangas-Sanjuan C, Rodriguez-Girondo M et al. Influence of
family history on relative and absolute colorectal cancer risk: a sys-
tematic review and meta-analysis. Clin Gastroenterol Hepatol 2019:
Sep 13. pii: S1542-3565(19)30995-4. doi:10.1016/j.
cgh.2019.09.007 [Epub ahead of print]
[96] Burt RW. Colon cancer screening. Gastroenterology 2000; 119:
837–853
[97] Kerber RA, Neklason DW, Samowitz WS et al. Frequency of familial
colon cancer and hereditary nonpolyposis colorectal cancer (Lynch
syndrome) in a large population database. Fam Cancer 2005; 4:
239–244
[98] Dove-Edwin I, Sasieni P, Adams J et al. Prevention of colorectal can-
cer by colonoscopic surveillance in individuals with a family history
of colorectal cancer: 16 year, prospective, follow-up study. BMJ
2005; 331: 1047
[99] Hatfield E, Green JS, Woods MO et al. Impact of colonoscopic
screening in familial colorectal cancer type X. Mol Genet Genomic
Med 2018; 6: 1021–1030
[100] Brenner H, Chang-Claude J, Seiler CM et al. Long-term risk of colo-
rectal cancer after negative colonoscopy. J Clin Oncol 2011; 29:
3761–3767
[101] Samadder NJ, Pappas L, Boucherr KM et al. Long-term colorectal
cancer incidence after negative colonoscopy in the state of Utah: the
effect of family history. Am J Gastroenterol 2017; 112: 1439–1447
[102] Hennink SD, van der Meulen-de Jong AE, Wolterbeek R et al. Ran-
domized comparison of surveillance intervals in familial colorectal
cancer. J Clin Oncol 2015; 33: 4188–4193
[103] Fuchs CS, Giovannucci EL, Colditz GA et al. A prospective study of
family history and the risk of colorectal cancer. N Engl J Med 1994;
331: 1669–1674
[104] Hemminki K, Li X. Familial colorectal adenocarcinoma from the
Swedish Family-Cancer Database. Int J Cancer 2001; 94: 743–748
[105] Andrieu N, Launoy G, Guillois R et al. Familial relative risk of colorec-
tal cancer: a population-based study. Eur J Cancer 2003; 39: 1904–
1911
[106] Johns LE, Kee F, Collins BJ et al. Colorectal cancer mortality in first-
degree relatives of early-onset colorectal cancer cases. Dis Colon
Rectum 2002; 45: 681–686
[107] Kune GA, Kune S, Watson LF. The role of heredity in the etiology of
large bowel cancer: data from the Melbourne Colorectal Cancer
Study. World J Surg 1989; 13: 124–129 ; discussion 9–31
[108] Samadder NJ, Smith KR, Hanson H et al. Increased risk of colorectal
cancer among family members of all ages, regardless of age of index
case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311.
e1-2
.jpg)
.png)
Комментарии